- Home
- HBT vs CERT Comparison
HBT vs CERT Comparison
Compare HBT & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | CERT |
|---|---|---|
| Founded | 1920 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | HBT | CERT |
|---|---|---|
| Price | $36.21 | $10.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 13 |
| Target Price | ★ $40.20 | $9.17 |
| AVG Volume (30 Days) | 110.8K | ★ 2.6M |
| Earning Date | 10-26-2026 | 11-05-2026 |
| Dividend Yield | ★ 2.76% | N/A |
| EPS Growth | 7.96 | ★ 87.50 |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $32.07 | N/A |
| Revenue Next Year | $23.72 | $2.54 |
| P/E Ratio | $32.29 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $22.37 | $4.45 |
| 52 Week High | $37.51 | $12.94 |
Technical Indicators
Market Signals| Indicator | HBT | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 64.80 |
| Support Level | $34.95 | $6.15 |
| Resistance Level | $36.96 | N/A |
| Average True Range (ATR) | 0.74 | 0.52 |
| MACD | 0.08 | 0.06 |
| Stochastic Oscillator | 81.82 | 97.98 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
About CERT Certara Inc.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.